Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Division of Pharmaceutical Chemistry, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Curr Drug Saf. 2022;17(2):114-120. doi: 10.2174/1574886316666210816115811.
The prevalence of potential drug-drug interactions (pDDIs) is indicative of the prevalence of actual drug-drug interactions and prescription quality. However, they are significantly understudied in Greece.
The objective of the study was to determine the prevalence of pDDIs among outpatients and identify factors associated with their occurrence.
Anonymous e-prescription data between 2012 and 2017 were obtained from community pharmacies in Thessaloniki, Greece. Patients taking more than one medication for at least three months were included. pDDIs were identified and categorized depending on their clinical significance using Drug Interactions Checker. Crude and adjusted odds ratios (ORs) with accompanying 95% confidence intervals (CIs) of risk factors of pDDIs occurrence were identified using multivariable logistic regression.
During the study period, 6,000 anonymous e-prescriptions (1,000 per year) satisfying the inclusion criteria were collected. The overall prevalence of major pDDIs was 17.4% (63.0% for moderate pDDIs). The most common major pDDIs were between amlodipine and simvastatin (22.8% of major interactions), followed by clopidogrel and omeprazole (6.4% of major interactions). Polypharmacy (≥5 concomitantly received medications) was associated with an increased risk of major pDDIs (adjusted OR, 5.72; 95% CI, 4.87-6.72); no associations were observed regarding age, sex, and number of prescribing physicians.
The prevalence of pDDIs in this study was higher than previously reported in other European countries, with polypharmacy being a potential risk factor. Those results argue for a need for improvement in the area of prescribing in Greece.
潜在药物相互作用（pDDI）的发生率表明了实际药物相互作用和处方质量的发生率。然而，在希腊，它们的研究明显不足。
本研究的目的是确定门诊患者中 pDDI 的发生率，并确定与 pDDI 发生相关的因素。
从希腊塞萨洛尼基的社区药房获取 2012 年至 2017 年期间的匿名电子处方数据。纳入至少连续服用三种药物三个月以上的患者。使用药物相互作用检查器根据其临床意义对 pDDI 进行识别和分类。使用多变量逻辑回归确定 pDDI 发生的危险因素的粗比值比（OR）和伴随的 95％置信区间（CI）。
在研究期间，共收集了 6000 份符合纳入标准的匿名电子处方（每年 1000 份）。主要 pDDI 的总体发生率为 17.4％（中度 pDDI 为 63.0％）。最常见的主要 pDDI 是氨氯地平和辛伐他汀之间（占所有主要相互作用的 22.8％），其次是氯吡格雷和奥美拉唑（占所有主要相互作用的 6.4％）。同时服用多种药物（≥5 种同时服用的药物）与发生主要 pDDI 的风险增加相关（调整后的 OR，5.72；95％CI，4.87-6.72）；年龄、性别和开处方医生的数量与 pDDI 无关。
本研究中 pDDI 的发生率高于先前在其他欧洲国家报道的发生率，同时服用多种药物是一个潜在的危险因素。这些结果表明，希腊在处方方面需要改进。
